KalVista Pharmaceuticals (KALV)

[Value_Investor]

The combined company will have total $48.011M Net Asset or shareholder's Equity Value while CBYL alone has $36.036M Net Asset. In another word after the merger the total Equity Value is increased by $11.975M! Note, the new company's assets value has not accounted in the Two New Drug's valuation which could be worth hundreds of millions of dollars...